# Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

> **NCT05334368** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 123 (estimated)

## Conditions studied

- Hypereosinophilic Syndrome

## Interventions

- **DRUG:** Depemokimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05334368
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-06
- **Primary completion:** 2028-12-19
- **Final completion:** 2028-12-19
- **Target enrollment:** 123 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05334368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05334368, "Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05334368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*